Harrow- 11.875% NT REDEEM 31/12/2027 USD 25 OverviewTrack Harrow- 11.875% NT REDEEM 31/12/2027 USD 25's EBIT ($-23M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Jun 30, 2026
Trailing 12 months ending Jun 30, 2026
As of the most recent data (June 2026), HROWM shows a EBIT of $-23M. That compares with $14M in the prior-year period — down 264.0% year over year. That is below the Healthcare sector average of $23B. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, HROWM's EBIT is now $-23M (was $14M) — a 264.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Harrow- 11.875% NT REDEEM 31/12/2027 USD 25 is outperforming or lagging.
The Healthcare sector average EBIT is about $23B. Harrow- 11.875% NT REDEEM 31/12/2027 USD 25 is at $-23M, which is lower that average. That is roughly 100.1% below the sector mean. Use the comparison chart on this page to see how HROWM stacks up against individual peers as well.
Tracking HROWM's ebit over time shows whether Harrow- 11.875% NT REDEEM 31/12/2027 USD 25 is scaling, shrinking, or reshaping that part of the business. The current reading is $-23M That compares with $14M in the prior-year period — down 264.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this ebit page, Stockcircle has Harrow- 11.875% NT REDEEM 31/12/2027 USD 25's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-23M) with ownership activity and broader fundamentals.
